Races of small molecule clinical trials for the treatment of COVID‐19: An up‐to‐date comprehensive review. Issue 1 (11th November 2021)

• Record Type: Journal Article
• Authors: Hu, Suwen; Jiang, Songwei; Qi, Xiang; Bai, Renren; Ye, Xiang‐Yang; Xie, Tian
• Is Part Of: Drug development research. Volume 83:Issue 1(2022)
• Page Start: 16
• Page End: 54
• Publication Date: 2021-11-11
• Subjects: anti‐viral agent -- COVID‐19 -- small molecules; Drug development -- Periodicals; Drugs -- Research -- Periodicals; 615.19
• DOI: 10.1002/ddr.21895
• Languages: English
• ISSNs: 0272-4391

Abstract

Abstract: The coronavirus disease‐19 (COVID‐19) pandemic has become a global threat since its first outbreak at the end of 2019. Several review articles have been published recently, focusing on the aspects of target biology, drug repurposing, and mechanisms of action (MOAs) for potential treatment. This review gathers all small molecules currently in active clinical trials, categorizes them into six sub‐classes, and summarizes their clinical progress. The aim is to provide the researchers from both pharmaceutical industries and academic institutes with the handful information and dataset to accelerate their research programs in searching effective small molecule therapy for treatment of COVID‐19.